Novartis Drug Failure Shakes the Race to Lower Lp(a) Cholesterol
A Novartis setback clouds a multibillion-dollar competition, raising pressure on Amgen and Eli Lilly to prove Lp(a)-lowering drugs actually prevent heart attacks.
A closely watched cholesterol drug trial has stumbled, and the reverberations are being felt across one of the pharmaceutical industry's most competitive and lucrative frontiers. Novartis recently reported a failure in its effort to demonstrate that reducing levels of lipoprotein(a) — a genetic risk factor for cardiovascular disease commonly known as Lp(a) — translates into fewer heart attacks and strokes. The setback is significant not just for Novartis, but for the broader scientific thesis underpinning an entire wave of next-generation cardiovascular therapies.
Lp(a) has long intrigued cardiologists because elevated levels are inherited, affect roughly one in five people globally, and have been strongly associated with cardiovascular risk. Yet association is not causation, and the pharmaceutical industry has been racing to prove that pharmacologically driving those levels down will deliver meaningful clinical benefit. Novartis' failure injects fresh uncertainty into that assumption — a reminder that biomarker improvement does not automatically translate into better patient outcomes, a lesson the industry has learned painfully before with other cholesterol-related targets.
Read more AstraZeneca COPD Drug Claims Two Phase-3 Wins, Eyes $5B Peak Sales →
The stakes are now considerably higher for Amgen and Eli Lilly, both of which have their own Lp(a)-targeting candidates advancing through clinical development. For these companies, billions of dollars in potential revenue hinge on whether their trials can succeed where Novartis could not. Investors and analysts will be scrutinizing the design differences between the competing programs, asking whether the Novartis result reflects a molecule-specific problem or a more fundamental challenge with the Lp(a) hypothesis itself.
The broader cardiovascular drug market context matters here. Cholesterol-lowering therapies have historically been blockbuster territory — statins alone reshaped preventive cardiology for decades. A proven Lp(a) therapy could command a similarly dominant commercial position given the scale of the at-risk population. But that promise now carries a sharper asterisk, and the pressure on remaining players to demonstrate not just biological activity but genuine clinical outcomes has never been more acute.
Continue reading at US Top News and Analysis.
